Medifast Stock Price, News & Analysis (NYSE:MED)

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1 year price targets for Medifast's stock. Their MED share price targets range from $80.00 to $82.00. On average, they predict the company's share price to reach $81.00 in the next year. This suggests a possible upside of 16.2% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $115.35 at the start of the year. Since then, MED stock has decreased by 39.6% and is now trading at $69.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) posted its quarterly earnings results on Monday, November, 6th. The specialty retailer reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $1.10. The specialty retailer had revenue of $235.87 million for the quarter, compared to the consensus estimate of $232.10 million. Medifast had a net margin of 9.84% and a trailing twelve-month return on equity of 76.08%. The firm's revenue for the quarter was down 39.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.32 earnings per share.

Medifast announced a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be given a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 9.47%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED.

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 9.66%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 60.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, MED will have a dividend payout ratio of 85.83% in the coming year. This indicates that the company may not be able to sustain their current dividend.
Read our dividend analysis for MED.

ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), First Trust SMID Cap Rising Dividend Achievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap Quality ETF (XSHQ), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Royce Quant Small-Cap Quality Value ETF (SQLV) and Global X Health & Wellness ETF (BFIT).

Medifast issued an update on its FY23 earnings guidance on Monday, November, 6th. The company provided earnings per share (EPS) guidance of $8.65-$9.55 for the period, compared to the consensus earnings per share estimate of $8.53. The company issued revenue guidance of $1.05-$1.07 billion, compared to the consensus revenue estimate of $1.09 billion.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast's stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.78%), Charles Schwab Investment Management Inc. (1.53%), JPMorgan Chase & Co. (1.40%), Jacobs Levy Equity Management Inc. (1.19%), Northern Trust Corp (1.16%) and AQR Capital Management LLC (1.12%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.